A GRAPPA working group highlighted the importance of screening for comorbidities to guide treatment selection among patients with psoriatic arthritis.
The adverse events related to COVID-19 vaccination were evaluated among patients with rheumatoid arthritis.
Lee EH, Lee KH, Kim J, et al. Comparing different delivery methods of fecal microbiota transplantation. Presented at: IDWeek 2022; October 19-23, 2022; Washington, DC. Poster 515.
Researchers studied the existing and changing patterns of pulmonary abnormalities among patients with rheumatoid arthritis.
Researchers investigated the associations between artificial sweeteners from all dietary sources and the risk for cardiovascular diseases.
Researchers assessed the modifiable factors associated with persistent medication adherence among patients with SLE.
Researchers analyzed the biomarkers which distinguish early from late relapses after biologics withdrawal among patients with rheumatoid arthritis.
Researchers studied humoral responses to 3 doses of the COVID-19 vaccine, as well as the effect of therapy, among patients with spondyloarthritis.
In a randomized clinical trial, researchers investigated the efficacy and safety of rituximab compared with placebo for patients with myasthenia gravis.
Researchers determined the association of physical activity and dietary factors with risk for rheumatoid arthritis.
Researchers sought to explore the duration of COVID-19 infection-related neurological and psychiatric risks, and whether they affect children and adults similarly, and whether COVID-19 variants differ in their risk profiles.
Researchers assessed maternal, neonatal, and fetal outcomes associated COVID-19 vaccination during pregnancy.
Researchers identified differences in multimorbidity and individual comorbidities among patients with rheumatoid arthritis, based on race and ethnicity.
Using independent cohorts, researchers conducted a meta-analysis of metabolomics on knee pain in primary osteoarthritis.
The novel cocrystal of febuxostat and telmisartan was evaluated for the treatment of comorbid hyperuricemia/gout and hypertension.
In a 5-year follow-up study, researchers identified the characteristics associated with cardiac function in patients with systemic lupus erythematosus.
Researchers noted the association of job insecurity and workplace activity limitations with rheumatic disease symptoms in young adulthood.
Researchers assessed the effect of biopsychosocial rehabilitation on patient-reported pain in inflammatory arthritis and osteoarthritis.
Researchers assessed the safety and efficacy of tocilizumab in the treatment of Familial Mediterranean Fever.
Using data from the CADERA trial, researchers performed a myocardial perfusion analysis among patients with early, untreated rheumatoid arthritis and healthy individuals.
Researchers assessed whether patients with rheumatic diseases receiving hydroxychloroquine therapy were at a lower risk for SARS-CoV-2 infection.
The American College of Rheumatology updated their guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis.
Researchers studied the effect of pirfenidone on the progression of lung disease in patients with rheumatoid arthritis-associated interstitial lung disease.
Researchers studied the association between hydroxychloroquine initiation and risk for incident arrhythmia among patients with rheumatoid arthritis and systemic lupus erythematosus.
Researchers sought to investigate the association between daytime napping frequency and the likelihood of essential hypertension or stroke.
Researchers studied the effects of tofacitinib on dactylitis and patient-reported outcomes in psoriatic arthritis.
Using data from the CARRA registry, researchers characterized medication use among children with lupus and assessed its association with race and ethnicity.
The real-world effectiveness of different second-line therapies – TNFi, abatacept, IL-6 inhibitors, and JAK inhibitors – were compared in an observational cohort study.
Researchers sought to determine the symptoms and risk factors associated with long COVID among nonhospitalized adults with confirmed acute SARS-CoV-2 infection.
Researchers assessed the effects of risankizumab therapy on patient-reported outcomes and the achievement of minimal clinically important differences in psoriatic arthritis.
